Citations (92)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Tom Dunne, Douglas Stewart, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar J. Bahlis & Victor H. Jimenez-Zepeda. (2021) Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic. Leukemia & Lymphoma 62:14, pages 3555-3557.
Read now
Read now
Abdullah M. Khan, Srinivas Devarakonda, Naresh Bumma, Maria Chaudhry & Don M. Benson$suffix/text()$suffix/text(). (2019) Potential of NK cells in multiple Myeloma therapy. Expert Review of Hematology 12:6, pages 425-435.
Read now
Read now
Benjamin W Teh, Monica A Slavin, Simon J Harrison & Leon J Worth. (2015) Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Review of Anti-infective Therapy 13:11, pages 1325-1336.
Read now
Read now
Paul J Neeson, Andy K Hsu, Yin R Chen, Heloise M Halse, Joanna Loh, Reece Cordy, Kate Fielding, Joanne Davis, Josh Noske, Alex J Davenport, Camilla A Lindqvist-Gigg, Robin Humphreys, Tsin Tai, H Miles Prince, Joseph A Trapani, Mark J Smyth & David S Ritchie. (2015) Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. OncoImmunology 4:9.
Read now
Read now
Juan Li, Beihui Huang, Ying Li, Dong Zheng, Zhenhai Zhou & Junru Liu. (2015) Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leukemia & Lymphoma 56:6, pages 1710-1717.
Read now
Read now
Constantin A. Dasanu, Prerna Mewawalla & Joanna Grabska. (2012) Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?. Current Medical Research and Opinion 28:7, pages 1129-1140.
Read now
Read now
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson & Paul G Richardson. (2009) Bortezomib in the management of multiple myeloma. Cancer Management and Research 1, pages 107-117.
Read now
Read now
Articles from other publishers (85)
H. Zijlstra, R. J. Pierik, A. M. Crawford, D. G. Tobert, N. Wolterbeek, J. H. F. Oosterhoff, D. Delawi, W. E. Terpstra, D. H. R. Kempen, J. J. Verlaan & J. H. Schwab. (2023) Analysis of complications and revisions after spine surgery in 270 multiple myeloma patients with spinal involvement. European Spine Journal 32:12, pages 4335-4354.
Crossref
Crossref
Niyati Seshagiri Sharma & Bibha Choudhary. (2023) Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma. Biomolecules 13:11, pages 1629.
Crossref
Crossref
Mehdi S. Salimy, Amy Z. Blackburn, Kyle Alpaugh, Santiago A. Lozano-Calderón, Hany S. Bedair & Christopher M. Melnic. (2023) Postoperative Outcomes in Total Hip and Total Knee Arthroplasty for Patients Who Have Multiple Myeloma. The Journal of Arthroplasty 38:11, pages 2269-2274.
Crossref
Crossref
H. Zijlstra, B.M. Striano, A.M. Crawford, O.Q. Groot, N. Raje, D.G. Tobert, C.G. Patel, N. Wolterbeek, D. Delawi, D.H.R. Kempen, J.J. Verlaan & J.H. Schwab. (2023) Neurologic Outcomes After Radiation Therapy for Severe Spinal Cord Compression in Multiple Myeloma. Journal of Bone and Joint Surgery 105:16, pages 1261-1269.
Crossref
Crossref
Michael Sheu, Sofia Molina Garcia, Meera Patel, Lauren Granat, Louis Williams, Jack Khouri, Sherif Mossad, Faiz Anwer & Aneela Majeed. (2023) Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection‐related hospitalizations in multiple myeloma patients. Hematological Oncology.
Crossref
Crossref
Brian M. Russell & David E. Avigan. (2023) Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. International Journal of Hematology 117:5, pages 652-659.
Crossref
Crossref
Lukas John, Kaya Miah, Axel Benner, Elias K. Mai, Katharina Kriegsmann, Michael Hundemer, Dorothee Kaudewitz, Carsten Müller-Tidow, Karin Jordan, Hartmut Goldschmidt, Marc S. Raab & Nicola Giesen. (2023) Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma. Frontiers in Oncology 13.
Crossref
Crossref
Lamees Al Kayyali, Zaid Abu Diak, Osama Abu Diak & Janusz Krawczyk. 2023. Recent Updates on Multiple Myeloma. Recent Updates on Multiple Myeloma.
Wen‐Ying Lin, Chun‐Kuang Tsai, Chiu‐Mei Yeh, Tin Chian, Yao‐Chung Liu, Hao‐Yuan Wang, Po‐Shen Ko, Ting‐An Lin, Liang‐Tsai Hsiao, Po‐Min Chen, Jyh‐Pyng Gau & Chia‐Jen Liu. (2022) Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. Cancer Medicine 12:3, pages 3013-3026.
Crossref
Crossref
Giuseppe Bertuglia, Lorenzo Cani, Alessandra Larocca, Francesca Gay & Mattia D’Agostino. (2022) Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?. International Journal of Molecular Sciences 23:24, pages 15879.
Crossref
Crossref
Damian Mikulski, Paweł Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra-Tybor & Tadeusz Robak. (2022) Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. Journal of Clinical Medicine 11:19, pages 5908.
Crossref
Crossref
Francesca Farina, V. Ferla, S. Marktel, D. Clerici, S. Mastaglio, T. Perini, C. Oltolini, R. Greco, F. Aletti, A. Assanelli, M. T. Lupo-Stanghellini, M. Bernardi, C. Corti, F. Ciceri & M. Marcatti. (2022) Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature. Frontiers in Oncology 12.
Crossref
Crossref
Alessandro Allegra, Marco Casciaro, Elena Lo Presti, Caterina Musolino & Sebastiano Gangemi. (2022) Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy. Biomolecules 12:6, pages 754.
Crossref
Crossref
Su-In Kim, Sung-Hoon Jung, Ho-Young Yhim, Jae-Cheol Jo, Ga-Young Song, Mihee Kim, Seo-Yeon Ahn, Jae-Sook Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim & Je-Jung Lee. (2022) Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. Blood Research 57:1, pages 51-58.
Crossref
Crossref
Jessica Caro, Marc Braunstein, Louis Williams, Benedetto Bruno, David Kaminetzky, Ariel Siegel, Beatrice Razzo, Serge Alfandari, Gareth J. Morgan, Faith E. Davies & Eileen M. Boyle. (2022) Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia 36:3, pages 613-624.
Crossref
Crossref
Noopur S Raje, Elias Anaissie, Shaji K Kumar, Sagar Lonial, Thomas Martin, Morie A Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O'Donnell, Andrew Yee, Jonathan L Kaufman, Adam D Cohen, Laurent Garderet, Ashutosh F Wechalekar, Evangelos Terpos, Navin Khatry, Ruben Niesvizky, Qing Yi, Douglas E Joshua, Tapan Saikia, Nelson Leung, Monika Engelhardt, Mohamad Mothy, Andrew Branagan, Ajai Chari, Anthony J Reiman, Brea Lipe, Joshua Richter, S Vincent Rajkumar, Jesús San Miguel, Kenneth C Anderson, Edward A Stadtmauer, Rao H Prabhala, Phillip L McCarthy & Nikhil C Munshi. (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet Haematology 9:2, pages e143-e161.
Crossref
Crossref
Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Martín Villalba & Alberto Anel. (2022) Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma. Cells 11:3, pages 392.
Crossref
Crossref
Alessandro Visentin, Matilde Rocchi, Anna Giulia Salvadori, Paola Del Bravo & Elda Righi. 2022. Paraproteinemia and Related Disorders. Paraproteinemia and Related Disorders
277
304
.
Nicole Balmaceda, Muhammad Aziz, Viveksandeep Thoguluva Chandrasekar, Brian McClune, Suman Kambhampati, Leyla Shune, Al-Ola Abdallah, Faiz Anwer, Aneela Majeed, Muzaffar Qazilbash, Siddhartha Ganguly, Joseph McGuirk & Ghulam Rehman Mohyuddin. (2021) Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21:1.
Crossref
Crossref
David J. Chung, Gunjan L. Shah, Sean M. DevlinLakshmi V. RamanathanSital DoddiMelissa S. Pessin, Elizabeth HooverLeeAnn T. Marcello, Jennifer C. YoungSawsan R. BoutemineEdith SerranoSaumya SharanSaddia MomotajLauren MargetichChristina D. BravoGenovefa A. PapanicolaouMini KambojAnthony R. MatoLindsey E. RoekerMalin HultcrantzSham MailankodyAlexander M. LesokhinSantosha A. Vardhana & David A. Knorr. (2021) Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discovery 2:6, pages 568-576.
Crossref
Crossref
Eyal Fuchs, Noa Lavi, Yariv Carasso, Ilana Oren & Emilia Hardak. (2021) Invasive Pulmonary Aspergillosis in Multiple Myeloma patients: A sizeable diagnosis in the era of novel anti‐myeloma therapies. Mycoses 64:10, pages 1298-1303.
Crossref
Crossref
Clarissa Heck, Sophie Steiner, Eva M. Kaebisch, Marco Frentsch, Friedrich Wittenbecher, Carmen Scheibenbogen, Leif G. Hanitsch, Axel Nogai, Philipp le Coutre, Lars Bullinger, Igor-Wolfgang Blau & Il-Kang Na. (2021) CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation. Frontiers in Immunology 12.
Crossref
Crossref
Guido Lancman, Dahniel L. SastowHearn J. Cho, Sundar JagannathDeepu MadduriSamir S. ParekhShambavi RichardJoshua RichterLarysa SanchezAjai Chari. (2021) Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discovery 2:5, pages 423-433.
Crossref
Crossref
Chhay Lim, Priyadarshini Sinha, Simon J. Harrison, Hang Quach, Monica A. Slavin & Benjamin W. Teh. (2021) Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. Clinical Lymphoma Myeloma and Leukemia 21:7, pages 444-450.e3.
Crossref
Crossref
Christie P. M. Verkleij, Marloes E. C. Broekmans, Mark van DuinKristine A. FrerichsRowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy Wong, Raluca I. Verona, Pieter SonneveldSonja ZweegmanHomer C. AdamsIIIIII, Tuna MutisNiels W. C. J. van de Donk. (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances 5:8, pages 2196-2215.
Crossref
Crossref
Luana Mota Ferreira, Jaderson Lima Cerezer & Mailine Gehrcke. (2021) Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review. Hematology, Transfusion and Cell Therapy 43:2, pages 185-190.
Crossref
Crossref
Almudena García-Ortiz, Yaiza Rodríguez-García, Jessica Encinas, Elena Maroto-Martín, Eva Castellano, Joaquín Teixidó & Joaquín Martínez-López. (2021) The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers 13:2, pages 217.
Crossref
Crossref
Chhay Lim, Priyadarshini Sinha, Simon J. Harrison, Hang Quach, Monica A. Slavin & Benjamin W. Teh. (2020) Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi‐centre cohort study. Mycoses 64:1, pages 30-34.
Crossref
Crossref
Benjamin W. Teh. 2021. Infection Management in Hematology. Infection Management in Hematology
77
105
.
Yue Wang, Wanjing Feng & Peng Liu. (2020) Genotype–immunophenotype analysis reveals the immunogenomic subtype and prognosis of multiple myeloma. Carcinogenesis 41:12, pages 1746-1754.
Crossref
Crossref
Xueshi Ye, Wanli Li, Jinwen Huang, Lifei Zhang & Ye Zhang. (2020) Cytotoxic T Cell Responses Induced by CS1/CRT Fusion DNA Vaccine in a Human Plasmacytoma Model. Frontiers in Oncology 10.
Crossref
Crossref
Helmi Alfarra, Jackson Weir, Stacy Grieve & Tony Reiman. (2020) Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Oliver C. Lomas, Tarek H. Mouhieddine, Sabrin Tahri & Irene M. Ghobrial. (2020) Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All. Cancers 12:6, pages 1554.
Crossref
Crossref
Hira Mian, Shakira J. Grant, Monika Engelhardt, Charlotte Pawlyn, Sara Bringhen, Sonja Zweegman, Claudia A.M. Stege, Ashley E. Rosko, Marie von Lilienfeld-Toal & Tanya M. Wildes. (2020) Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of Geriatric Oncology 11:5, pages 764-768.
Crossref
Crossref
Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Berris van Kessel, Martijn W. Heymans, Lisa C. Holthof, Christie P.M. Verkleij, Rengasamy Boominathan, Bhavesh Vaidya, Jocelyn Sendecki, Amy Axel, Francois Gaudet, Kodandaram Pillarisetti, Sonja Zweegman, Homer C. AdamsIIIIII, Tuna Mutis & Niels W.C.J. van de Donk. (2020) Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research 26:9, pages 2203-2215.
Crossref
Crossref
Abdullah S. Al Saleh, Taimur Sher & Morie A. Gertz. (2020) Multiple Myeloma in the Time of COVID-19. Acta Haematologica 143:5, pages 410-416.
Crossref
Crossref
Mohammad Faizan Zahid, Natasha Ali, Myra Nasir, Maria Haider Baig, Mustafa Iftikhar, Syed Usman Bin Mahmood, Arhama Malik, Sara Atif & Mohammad Asim Beg. (2019) Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan. Hematology, Transfusion and Cell Therapy 41:4, pages 292-297.
Crossref
Crossref
Jorge Vela-Ojeda, Miriam America García-Ruiz Esparza, Abraham Majluf-Cruz, Jaime García-Chavez, Laura Arcelia Montiel-Cervantes, Elba Reyes-Maldonado, Alvaro Hernandez-Caballero & Maria Guadalupe Rodríguez-González. (2019) Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. International Journal of Hematology 110:3, pages 306-312.
Crossref
Crossref
Ghulam Rehman Mohyuddin & Muzaffar H. Qazilbash. (2019) The therapeutic role of natural killer cells in multiple myeloma. ADVANCES IN CELL AND GENE THERAPY 2:2, pages e49.
Crossref
Crossref
Asma M. Al-Jasser & Khalid Ahmed Al-Anazi. 2019. Update on Multiple Myeloma. Update on Multiple Myeloma.
Kristine A. Frerichs, Patricia W.C. Bosman, Inger S. Nijhof, Sonja Zweegman & Niels W.C.J. van de Donk. (2019) Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. Clinical Lymphoma Myeloma and Leukemia 19:1, pages e9-e11.
Crossref
Crossref
Starling A. Sim, Vivian K.Y. Leung, David Ritchie, Monica A. Slavin, Sheena G. Sullivan & Benjamin W. Teh. (2018) Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing. Biology of Blood and Marrow Transplantation 24:7, pages 1490-1496.
Crossref
Crossref
Pan Liu, Yanxia Jin, Haseeb Sattar, Hailing Liu, Weiling Xie & Fuling Zhou. (2018) Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities. Journal of Leukocyte Biology 103:5, pages 821-828.
Crossref
Crossref
Hailing Liu, Yunbao Pan, Shan Meng, Wanggang Zhang & Fuling Zhou. (2017) Current treatment options of T cell-associated immunotherapy in multiple myeloma. Clinical and Experimental Medicine 17:4, pages 431-439.
Crossref
Crossref
Benjamin W. Teh, Simon J. Harrison, Cody Charles Allison, Monica A. Slavin, Tim Spelman, Leon J. Worth, Karin A. Thursky, David Ritchie & Marc Pellegrini. (2017) Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. Frontiers in Immunology 8.
Crossref
Crossref
Li Ying, Tong YinHui, Zheng Yunliang & Haozhen Sun. (2017) Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8:28, pages 46593-46600.
Crossref
Crossref
Tracy King & Beth Faiman. (2017) Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
. Clinical Journal of Oncology Nursing 21:2, pages 240-249.
Crossref
Crossref
John A. Snowden, Diana M. Greenfield, Jennifer M. Bird, Elaine Boland, Stella Bowcock, Abigail Fisher, Eric Low, Monica Morris, Kwee Yong & Guy Pratt. (2017) Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. British Journal of Haematology 176:6, pages 888-907.
Crossref
Crossref
Li Junxun, Liu Junru, Chen Meilan, Liang Chujia, Chen Shaoqian, Zhan Jieyu, Ye Zhuangjian, Zhang Fan, Ouyang Juan, Cheng Jing & Li Juan. (2016) Three Patients with Multiple Myeloma Developing Secondary Lymphoblastic Leukemia: Case Reports and Review of the Literature. Tumori Journal 102:2_suppl, pages S131-S136.
Crossref
Crossref
Gordana Konjević, Ana Vuletić, Katarina Mirjačić Martinović, Nataša Colović, Milica Čolović & Vladimir Jurišić. (2016) Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma. Journal of Clinical Pathology 69:11, pages 1009-1016.
Crossref
Crossref
Ensaf Al-Hujaily, Robyn Oldham, Parameswaran Hari & Jeffrey Medin. (2016) Development of Novel Immunotherapies for Multiple Myeloma. International Journal of Molecular Sciences 17:9, pages 1506.
Crossref
Crossref
Junxun Li, Jieyu Zhan, Fan Zhang, Zhuangjian Ye & Juan Ouyang. (2016) Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report. Oncology Letters 12:2, pages 847-856.
Crossref
Crossref
Sung-Eun Lee, Ji-Young Lim, Da-Bin Ryu, Tae Woo Kim, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Myungshin Kim & Chang-Ki Min. (2016) Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. Cancer Immunology, Immunotherapy 65:8, pages 983-994.
Crossref
Crossref
Djordje Atanackovic, Sabarinath V. Radhakrishnan, Neelam Bhardwaj & Tim Luetkens. (2016) Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. British Journal of Haematology 172:5, pages 685-698.
Crossref
Crossref
Tetsuo Hasegawa, Yoshinobu Aisa, Kengo Shimazaki, Chisako Ito & Tomonori Nakazato. (2016) Cytomegalovirus reactivation in patients with multiple myeloma. European Journal of Haematology 96:1, pages 78-82.
Crossref
Crossref
Wilson I. Gonsalves, Kelly Godby, Shaji K. Kumar & Luciano J. Costa. (2015) Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. American Journal of Hematology 91:1, pages 101-108.
Crossref
Crossref
Benjamin W. Teh, Simon J. Harrison, Leon J. Worth, Tim Spelman, Karin A. Thursky & Monica A. Slavin. (2015) Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. British Journal of Haematology 171:1, pages 100-108.
Crossref
Crossref
T Dosani, M Carlsten, I Maric & O Landgren. (2015) The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer Journal 5:4, pages e306-e306.
Crossref
Crossref
M. Binsfeld, K. Fostier, J. Muller, F. Baron, R. Schots, Y. Beguin, R. Heusschen & J. Caers. (2014) Cellular immunotherapy in multiple myeloma: Lessons from preclinical models. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846:2, pages 392-404.
Crossref
Crossref
A Surov, A G Bach, A Tcherkes & D Schramm. (2014) Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma. The British Journal of Radiology 87:1041, pages 20140185.
Crossref
Crossref
Barbara A Qurollo, Nandhakumar Balakrishnan, Coralie Zegre Cannon, Ricardo G Maggi & Edward B Breitschwerdt. (2014)
Co-infection with
Anaplasma platys, Bartonella henselae, Bartonella koehlerae
and ‘
Candidatus
Mycoplasma haemominutum’ in a cat diagnosed with splenic plasmacytosis and multiple myeloma
. Journal of Feline Medicine and Surgery 16:8, pages 713-720.
Crossref
Crossref
M A Dimopoulos, X Leleu, A Palumbo, P Moreau, M Delforge, M Cavo, H Ludwig, G J Morgan, F E Davies, P Sonneveld, S A Schey, S Zweegman, M Hansson, K Weisel, M V Mateos, T Facon & J F S Miguel. (2014) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28:8, pages 1573-1585.
Crossref
Crossref
Sarah M. Tete, Marc Bijl, Surinder S. Sahota & Nicolaas A. Bos. (2014) Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Frontiers in Immunology 5.
Crossref
Crossref
D Atanackovic, T Luetkens & N Kröger. (2013) Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 28:5, pages 993-1000.
Crossref
Crossref
Tomer M. Mark, Morton Coleman & Ruben Niesvizky. (2014) Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leukemia Research 38:5, pages 517-524.
Crossref
Crossref
Benjamin W. Teh, Simon J. Harrison, Marc Pellegrini, Karin A. Thursky, Leon J. Worth & Monica A. Slavin. (2014) Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. Blood Reviews 28:2, pages 75-86.
Crossref
Crossref
Christopher P. Conlon. 2013. Myeloma. Myeloma
276
287
.
Ruben Niesvizky. (2013) Immunomodulatory agents changing the landscape of multiple myeloma treatment. Critical Reviews in Oncology/Hematology 88, pages S1-S4.
Crossref
Crossref
Elke Bogner & Gabriele Pecher. (2013) Pattern of the Epitope-Specific IgG/IgM Response against Human Cytomegalovirus in Patients with Multiple Myeloma. Clinical and Vaccine Immunology 20:8, pages 1298-1304.
Crossref
Crossref
B.W. Teh, A.S. Khot, S.J. Harrison, H.M. Prince & M.A. Slavin. (2013) A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. Transplant Infectious Disease 15:4, pages E134-E138.
Crossref
Crossref
Peter A Forsberg & Tomer M Mark. (2013) Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncology 9:7, pages 939-948.
Crossref
Crossref
Jae-Sook AhnSung Yoon RewDeok-Hwan YangSung-Hoon JungSeung-Ji KangMi-Young KimSeung-Shin LeeYeo-Kyeoung KimHyeoung-Joon KimJe-Jung Lee. (2013)
Poor prognostic significance of
Mycobacterium tuberculosis
infection during bortezomib-containing chemotherapy in patients with multiple myeloma
. Blood Research 48:1, pages 35.
Crossref
Crossref
Hui Y. Lim, David Francis, Jonathan Yeoh & Lyndell L. Lim. (2013) CYTOMEGALOVIRUS RETINITIS AFTER TREATMENT WITH LENALIDOMIDE FOR MULTIPLE MYELOMA. Retinal Cases & Brief Reports 7:2, pages 172-175.
Crossref
Crossref
Netanel Horowitz, Ilana Oren, Noa Lavi, Tsila Zuckerman, Noam Benyamini, Zipi Kra-Oz, Viki Held & Irit Avivi. (2012) New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib. Bone Marrow Research 2012, pages 1-7.
Crossref
Crossref
Ivan Borrello. (2012) Can we change the disease biology of multiple myeloma?. Leukemia Research 36, pages S3-S12.
Crossref
Crossref
Abhisek Swaika, Aneel Paulus, Kena C. Miller, Taimur Sher, Nikolaos G. Almyroudis, Donna Ball, Margaret Wood, Aisha Masood, Kelvin Lee & Asher A. Chanan-Khan. (2012) Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients. The Journal of Supportive Oncology 10:4, pages 155-159.
Crossref
Crossref
Constantin A Dasanu. (2011) Immune alterations in untreated and treated multiple myeloma. Journal of Oncology Pharmacy Practice 18:2, pages 257-263.
Crossref
Crossref
Marcia Garnica & Marcio Nucci. 2011. Pulmonary Involvement in Patients with Hematological Malignancies. Pulmonary Involvement in Patients with Hematological Malignancies
337
348
.
Faith Davies & Rachid Baz. (2010) Lenalidomide mode of action: linking bench and clinical findings. Blood Reviews 24, pages S13-S19.
Crossref
Crossref
G. N. KALAMBOKIS, L. CHRISTOU & E. V. TSIANOS. (2009) Multiple myeloma presenting with an acute bacterial infection. International Journal of Laboratory Hematology 31:4, pages 375-383.
Crossref
Crossref
Asher A. Chanan-Khan, Pieter Sonneveld, Jean-Luc Harousseau & Paul G. Richardson. (2009) Reply to C.A. Dasanu et al. Journal of Clinical Oncology 27:13, pages 2294-2296.
Crossref
Crossref
Constantin A. Dasanu & Doru T. Alexandrescu. (2009) Does Bortezomib Induce De Facto Varicella Zoster Virus Reactivation in Patients With Multiple Myeloma?. Journal of Clinical Oncology 27:13, pages 2293-2294.
Crossref
Crossref
Robert P. Baughman & Elyse E. Lower. 2009. Pulmonary Infection in the Immunocompromised Patient. Pulmonary Infection in the Immunocompromised Patient
53
93
.
L Gil, M Kozlowska-Skrzypczak, A Mol, D Poplawski, J Styczynski & M Komarnicki. (2008) Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplantation 43:2, pages 121-126.
Crossref
Crossref
Asher Chanan-KhanPieter SonneveldMichael W. SchusterEdward A. StadtmauerThierry FaconJean-Luc HarousseauDina Ben-YehudaSagar LonialHartmut GoldschmidtDonna ReeceRachel NeuwirthKenneth C. AndersonPaul G. Richardson. (2008) Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. Journal of Clinical Oncology 26:29, pages 4784-4790.
Crossref
Crossref